tiprankstipranks

Akari Therapeutics Delays Yearly Financial Report

Story Highlights
Akari Therapeutics Delays Yearly Financial Report

Akari Therapeutics ( (AKTX) ) has released a notification of late filing.

Akari Therapeutics has filed a Form 12b-25, notifying a delay in submitting its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the need for additional time to finalize financial statements due to accounting complexities from a recent business combination and other accounting items. The company anticipates filing the report within the fifteen-day extension period allowed. Significant changes in financial results are expected, including increased operating expenses and net loss due to merger-related activities. Akari Therapeutics is committed to ongoing compliance, as indicated by the signature of its President and CEO, Samir R. Patel, M.D.

More about Akari Therapeutics

YTD Price Performance: 4.96%

Average Trading Volume: 36,445

Technical Sentiment Signal: Buy

Current Market Cap: $15.42M

See more insights into AKTX stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App